For as long as the semiconductor market has existed, Intel (INTC) remained the biggest company in that particular line of business and dominated the market for decades. Over the past few years, it had faced intense competition from a range of companies and eventually lost its place as the highest selling company for semiconductors.
However, all that belongs in the past as the semiconductor giant has managed claw back its market share and has emerged as the leader of the market once again. The company had lost out its crown to Samsung but it seems market forces have ensured that the world’s biggest chip maker is back at the top.
Intel’s return to the top of the market was reported by IC Insights and according to the report, it appears that the turmoil in the semiconductor market is the primary reason behind the development. The report stated that after two full years of Samsung emerging as the world’s biggest chipmaker, Intel is now all set to regain its throne by the time 2019 ends.
When the whole market was in the middle of an upswing over the past few years, Samsung consolidated its position at the top through soaring sales in DRAM and NAND. However, the downturn in the market has eaten into the sales of those products and helped Intel regain its position at the top. In Q1 2019, Intel has sold 23% more than Samsung and it is a trend that is expected to continue for the rest of the year.
While it is true that the unseating of an industry leader after two years at the top can often appear unexpected, many experts actually predicted the change of fortune for Samsung. Industry experts had already predicted a downturn in the DRAM market and in addition to that, there had also been predictions about significant losses for companies dealing in DRAM.
Considering the fact that Samsung was so heavily dependent on DRAM sales, the company’s unseating was perhaps not entirely unexpected. Unless the market recovers significantly there is every chance that Intel might hold on to its position for some time.
Acadia (ACAD) Stock Price is up 60% This Month; Bullish Signal For Biotechs?
One sector that has always been a favorite of investors of all varieties is the pharmaceutical sector and all investors like a turnaround story. Over the years, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had been one of the better-known strugglers in the industry. That was reflected in the stock price as well. But recent developments have breathed new life in the stock, which could be an indicator for the biotech industry at large.
Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)
There has been no lack of attention on biotech penny stocks this year. At the beginning of August, one small biotech stock broke to highs of over $10 from a starting price below $2 a share after releasing news. PharmaCyte Biotech (PMCB) focuses on ways to effectively deliver treatments to patients with diseases ranging from cancer to diabetes.
The company’s proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®is the platform that the company uses to develop its therapy delivery methods. For most of the quarter, shares of PMCB stock have traded between $0.033 and $0.04 with volume recently surging.
On September 12, PharmaCyte saw more than 4 million shares trade; well above its daily average. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress. The company brought on Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center.
Second, the company has been ramping up for a much-anticipated shareholder update call on September 20. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to treat locally advanced, inoperable pancreatic cancer and developments related to PharmaCyte’s product pipeline on which PharmaCyte has been working and that have not yet been reported in a press release.
Acadia (ACAD) Stock Price: Important Developments
People who had held on to the stock through the barren years got a nice boost recently. This came after Acadia’s well-known medicine Nuplazid recorded better than expected sales. In addition to that, there were encouraging results from a dementia-driven psychosis study. Hence, it is important to figure out whether it is perhaps time to buy the stock.
While the signs are no doubt encouraging, it is important to note that data reveals that around 60,000 people in the United States are diagnosed with Parkinson’s every year. Out of those, a large proportion (50% to 80%) suffers from dementia. Hence it can be argued that the market is simply not too big for Acadia’s Nuplazid.
Moreover, different types of dementia are brought on by Alzheimer’s disease, which is why all of it might not actually fall into Acadia’s lap. That being said, it is also well known that antipsychotic drugs have only been approved for the treatment of Parkinson’s and hence the Alzheimer’s market is already out of the question.
Projections suggest that the sale of Nuplazid could grow to more than $1 billion in 2023 from $224 million in 2018. While that is encouraging, it is also important to note that the growth has been priced into the Acadia stock price.
However, if Acadia’s plans for growth somehow run into any trouble, then there is every chance of the stock price plummeting once again. The company is recovering and there is some time before the patient population for Nuplazid can be expanded sufficiently. In the meantime, investors need to be a bit more patient.
Shares of ACAD are up over 60% over the past week and made a new multi-year high of $43.98.
Advanced Micro Devices (AMD) Stock Price Consolidates After the Recent Rally: What Next?
It sometimes so happens that the price action and activity around a stock reaches a decisive stage, from which it can go only one way or another. In other words, it is the moment when the future of a stock is a straight shootout between the bulls and the bears.
The Advanced Micro Devices, Inc. (NASDAQ:AMD) stock has now reached such a stage according to keen observers and hence the stock is now trading within a very narrow range as the squeeze continues. In such a situation, it is only natural for investors to wonder which way this whole thing is going to go in the short term.
First and foremost, it is important to point out that since Lisa Su took over as the Chief Executive Officer in 2014, AMD has managed to stage a remarkable turnaround. Although the process has been slow, it proved to be highly lucrative for those investors who were patient. The stock has risen steadily over the past three years and rallied from $2 to around $30.
However, at the time, the investors had backed the company’s turnaround but now the story has changed and the turnaround has concluded. The bulls seem to think that the run is going to continue while bears believe that with the conclusion of the turnaround, the stock is all set to fall.
After all, if there is no further upside, then there is no point in holding the stock. This has caused uncertainty in the stock and its price action. Analysts believe that while the turnaround story had resulted in enormous gains for many investors, the stock is now expected to mirror the performance of the broader market. This factor lays credence to the bears’ position and moreover, the small matter of a looming Presidential election needs to be considered as well. Markets are generally flat in the lead-up and hence, analysts believe that although AMD might continue to be range-bound, it is unlikely that it is going to go on a rally.
Stock Price Newsletter – September 18, 2019
4 Penny Stocks Catching Attention This Week
Several economic and sector events have sparked interest in a number of small-cap and micro-cap stocks this week.
Airline Stocks In Focus; Spur Interest In Detection Tech Companies?
The latest mix of attacks and focus on airlines could have a different impact on sectors like weapons detection & defense. What could this mean for stocks to watch this week?
Top Biotech Stocks To Watch This Week
The values of biotech equities, however, do generally start to pick up as the year winds down. The underlying reason is that the latter part of the year is chock-full of key data readouts, regulatory decisions, and thousands of scientific conferences across the globe.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Biotechnology1 week ago
This Biotech Stock Could Hold the Key to a Multi-Billion Dollar Market Shake-up
Biotechnology2 weeks ago
Tiziana Life Sciences (TLSA) Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma
Biotechnology1 week ago
Multi-Billion Dollar Markets Are Ready For A Shake-Up; 1 Biotech Stock Could Hold The Key
Featured3 days ago
Tiziana Life Sciences (TLSA) Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers
Featured1 week ago
This Biotech Stock is Looking to Deliver Huge Positive Change
Featured3 days ago
Top 4 Penny Stocks To Watch This Week
Biotechnology1 week ago
Are Biotech Stocks Setting The Stage For Another Bull Trend?
Biotechnology1 week ago
Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers